報價延遲最少15分鐘:2025/11/19 07:44 EST
盤前時段
|
||||
|
8.82 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.82
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.57/-4.57
|
|
企業價值
375.36M
|
| 資產負債 |
|
每股賬面淨值
8.91
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
210.78M
|
|
每股收益
2.28
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/11/19 07:44 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. |
